WASHINGTON (Reuters) - U.S. health officials have halted enrollment of new patients in a clinical trial of GlaxoSmithKline Plc’s diabetes pill Avandia while regulators consider if the drug should stay on the market.
WASHINGTON (Reuters) - U.S. health officials have halted enrollment of new patients in a clinical trial of GlaxoSmithKline Plc’s diabetes pill Avandia while regulators consider if the drug should stay on the market.